Streetbeat News

Products Services

ONVO

Organovo shares surged following the announcement of positive Phase 2 results for FXR314, showing a significant reduction in liver fat content compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:50 pm

SGML

Sigma Lithium Corporation (SGML) has begun loading its 8th shipment of 22,000 tonnes of high-purity lithium concentrate, achieving a premium fixed price of $1,333/t, equivalent to $1,160/t net of VAT. This price represents a significant increase over previous prices and is 8.75% of the LME Lithium Hydroxide CIF market price. 85% of the shipment's value has been prepaid, indicating strong market demand and confidence in Sigma Lithium's product. The company plans to continue optimizing its commercial strategy for future production.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:46 pm

MRNS

Marinus Pharmaceuticals shares are trading lower following an update on the Phase 3 RAISE trial and preliminary Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:46 pm

GS

LGVN

ONVO

Goldman Sachs (GS) shares rose after reporting Q1 earnings surpassing expectations. Longeveron (LGVN) surged as its Alzheimer's treatment trial will be featured at the 2024 AAIC. Organovo (ONVO) jumped on positive Phase 2 results for its liver treatment FXR314.

Portfolio Pulse from ryanfaloona@benzinga.com

April 15, 2024 | 12:44 pm

EIX

MSFT

SPRU

Spruce Power Holding Corporation (NYSE:SPRU) announced leadership changes with Chris Hayes, the current Chairman of the Board, appointed as President and CEO, effective April 12, 2024. Dr. Audrey Lee joins the Board of Directors. Hayes brings extensive experience in sustainable infrastructure and was a founder of Alturus and Altenex, the latter acquired by Edison International (NYSE:EIX) in 2015. Dr. Lee, currently Senior Director of Datacenter Energy Strategy at Microsoft (NASDAQ:MSFT), brings 20 years of clean energy experience to the board. The company aims to leverage its technology platform and 75,000 home solar assets to create new revenue streams.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:41 pm

IPX

IperionX Limited (NASDAQ:IPX) has entered into a framework agreement with United Stars Holdings, Inc. to supply up to 80 metric tons of titanium products annually over a 10-year term. This partnership aims to support the U.S. defense and advanced technology sectors with sustainable, low-cost titanium products. United Stars, a key supplier to major companies across various sectors, aligns with IperionX's mission to re-shore the U.S. titanium supply chain and enhance manufacturing independence.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:40 pm

CRMD

CorMedix has announced the U.S. inpatient commercial availability of DefenCath, marking a significant milestone for the company. This development could potentially boost CorMedix's market presence and financial performance by expanding the accessibility of DefenCath to a broader patient base in the inpatient setting.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:40 pm

ICCM

IceCure Medical announced the final results of its ICE3 breast cancer cryoablation trial, submitting data to the FDA for marketing authorization to treat early-stage breast cancer. The data, presented at the ASBrS Annual Meeting and awarded the Scientific Impact Award, supports the use of cryoablation for early stage T1 invasive breast cancer with adjuvant hormone therapy. The company anticipates enhanced usage upon approval, citing the availability of a reimbursement code for facility expenses and the cost-effectiveness of its ProSense® cryoablation system.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:37 pm

RARE

Ultragenyx shares are trading lower following the announcement of interim Phase 1/2 data for GTX-102 in patients with Angelman Syndrome, indicating potentially disappointing results.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:36 pm

THAR

Tharimmune has established a Scientific Advisory Board comprising leading experts in immunology, liver diseases, protein engineering, and antibody drug conjugates to advance its clinical-stage lead in chronic liver disease and its early-stage tunable knob domains for generating antibody drug conjugate biotherapeutics.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:35 pm